Sam Slutsky
Stock Analyst at LifeSci Capital
(4.96)
# 114
Out of 5,074 analysts
698
Total ratings
49.8%
Success rate
44.7%
Average return
Main Sectors:
Stocks Rated by Sam Slutsky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Reiterated: Buy | $43 → $15 | $19.20 | -21.88% | 29 | Oct 6, 2026 | |
| CLDX Celldex Therapeutics | Reiterated: Buy | $64 | $28.97 | +120.92% | 46 | Oct 3, 2026 | |
| DBVT DBV Technologies | Reiterated: Buy | $45 | $9.68 | +364.88% | 14 | Sep 30, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $22.50 | $10.65 | +111.27% | 12 | Sep 30, 2026 | |
| OBX Obsidian Therapeutics | Reiterated: Buy | $43 | $13.94 | +208.46% | 2 | Sep 29, 2026 | |
| IMVT Immunovant | Reiterated: Buy | $53 | $29.10 | +82.13% | 74 | Sep 26, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Buy | $8 | $1.71 | +367.84% | 25 | Sep 26, 2026 | |
| ORKA Oruka Therapeutics | Reiterated: Buy | $175 | $81.15 | +115.65% | 25 | Sep 23, 2026 | |
| ABVX ABIVAX Société Anonyme | Reiterated: Buy | $170 → $168 | $90.23 | +86.19% | 36 | Sep 22, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $16 | $7.02 | +127.92% | 46 | Sep 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $21.71 | +107.28% | 9 | Sep 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55 | $31.31 | +75.66% | 52 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56 | $7.22 | +675.62% | 7 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $116 | $92.33 | +25.64% | 59 | Sep 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $14.50 | +210.34% | 2 | Sep 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.2162 | - | 23 | Sep 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 → $70 | $41.93 | +66.94% | 38 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $108 | $62.58 | +72.58% | 34 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.19 | - | 29 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.53 | +226.80% | 33 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $2.58 | +520.16% | 14 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $225 → $236 | $126.39 | +86.72% | 25 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.16 | $0.619 | n/a | 11 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.85 | n/a | 23 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $33.21 → $20.41 | $2.13 | n/a | 30 | Apr 18, 2023 |
ArriVent BioPharma
Oct 6, 2026
Reiterated: Buy
Price Target: $43 → $15
Current: $19.20
Upside: -21.88%
Celldex Therapeutics
Oct 3, 2026
Reiterated: Buy
Price Target: $64
Current: $28.97
Upside: +120.92%
DBV Technologies
Sep 30, 2026
Reiterated: Buy
Price Target: $45
Current: $9.68
Upside: +364.88%
Eupraxia Pharmaceuticals Inc.
Sep 30, 2026
Reiterated: Buy
Price Target: $22.50
Current: $10.65
Upside: +111.27%
Obsidian Therapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: $43
Current: $13.94
Upside: +208.46%
Immunovant
Sep 26, 2026
Reiterated: Buy
Price Target: $53
Current: $29.10
Upside: +82.13%
Pyxis Oncology
Sep 26, 2026
Reiterated: Buy
Price Target: $8
Current: $1.71
Upside: +367.84%
Oruka Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: $175
Current: $81.15
Upside: +115.65%
ABIVAX Société Anonyme
Sep 22, 2026
Reiterated: Buy
Price Target: $170 → $168
Current: $90.23
Upside: +86.19%
Olema Pharmaceuticals
Sep 19, 2026
Reiterated: Buy
Price Target: $16
Current: $7.02
Upside: +127.92%
Sep 18, 2026
Reiterated: Buy
Price Target: $45
Current: $21.71
Upside: +107.28%
Sep 15, 2026
Reiterated: Buy
Price Target: $55
Current: $31.31
Upside: +75.66%
Sep 11, 2026
Reiterated: Buy
Price Target: $56
Current: $7.22
Upside: +675.62%
Sep 8, 2026
Reiterated: Buy
Price Target: $116
Current: $92.33
Upside: +25.64%
Sep 5, 2026
Reiterated: Buy
Price Target: $45
Current: $14.50
Upside: +210.34%
Sep 2, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.2162
Upside: -
Aug 8, 2026
Rated: Buy
Price Target: $60 → $70
Current: $41.93
Upside: +66.94%
Aug 7, 2026
Reiterated: Buy
Price Target: $108
Current: $62.58
Upside: +72.58%
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.19
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: $5
Current: $1.53
Upside: +226.80%
Aug 5, 2026
Reiterated: Buy
Price Target: $16
Current: $2.58
Upside: +520.16%
Aug 5, 2026
Reiterated: Buy
Price Target: $225 → $236
Current: $126.39
Upside: +86.72%
Dec 14, 2023
Reiterated: Hold
Price Target: $1.16
Current: $0.619
Upside: n/a
Aug 9, 2023
Rated: Hold
Price Target: n/a
Current: $5.85
Upside: n/a
Apr 18, 2023
Upgraded: Hold
Price Target: $33.21 → $20.41
Current: $2.13
Upside: n/a